Cargando…

SARS-CoV-2 infections in 165 countries over time

Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and...

Descripción completa

Detalles Bibliográficos
Autor principal: Louca, Stilianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413603/
https://www.ncbi.nlm.nih.gov/pubmed/34487852
http://dx.doi.org/10.1016/j.ijid.2021.08.067
_version_ 1783747672152211456
author Louca, Stilianos
author_facet Louca, Stilianos
author_sort Louca, Stilianos
collection PubMed
description Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and different testing strategies. Methods: This study uses death count statistics, age-dependent infection fatality risks, and stochastic modeling to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among adults (aged 20 years or older) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison with previous nationwide seroprevalence surveys. Results: The estimates presented reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) was estimated as 98% (95% confidence interval [CI] 93–100%) for Peru, 83% (95% CI 61–94%) for Brazil, and 36% (95% CI 23–61%) for the United States. Conclusions: The time-resolved estimates presented expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries.
format Online
Article
Text
id pubmed-8413603
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-84136032021-09-03 SARS-CoV-2 infections in 165 countries over time Louca, Stilianos Int J Infect Dis Article Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and different testing strategies. Methods: This study uses death count statistics, age-dependent infection fatality risks, and stochastic modeling to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among adults (aged 20 years or older) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison with previous nationwide seroprevalence surveys. Results: The estimates presented reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) was estimated as 98% (95% confidence interval [CI] 93–100%) for Peru, 83% (95% CI 61–94%) for Brazil, and 36% (95% CI 23–61%) for the United States. Conclusions: The time-resolved estimates presented expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries. The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-10 2021-09-03 /pmc/articles/PMC8413603/ /pubmed/34487852 http://dx.doi.org/10.1016/j.ijid.2021.08.067 Text en © 2021 The Author Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Louca, Stilianos
SARS-CoV-2 infections in 165 countries over time
title SARS-CoV-2 infections in 165 countries over time
title_full SARS-CoV-2 infections in 165 countries over time
title_fullStr SARS-CoV-2 infections in 165 countries over time
title_full_unstemmed SARS-CoV-2 infections in 165 countries over time
title_short SARS-CoV-2 infections in 165 countries over time
title_sort sars-cov-2 infections in 165 countries over time
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413603/
https://www.ncbi.nlm.nih.gov/pubmed/34487852
http://dx.doi.org/10.1016/j.ijid.2021.08.067
work_keys_str_mv AT loucastilianos sarscov2infectionsin165countriesovertime